Note: Ms. Gnatiuc, Ms. Wade, and Dr. Emberson had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the analysis.
Financial Support: This study was supported by grants from the Wellcome Trust (058299/Z/99, 090532, 098381), Mexican Health Ministry, National Council of Science and Technology for Mexico, Cancer Research UK, British Heart Foundation, and United Kingdom Medical Research Council (MRC-UK). Dr. Herrington is funded by an MRC-UK–Kidney Research UK Professor David Kerr Clinician Scientist Award.
Disclosures: Ms. Wade reports grants from the MRC during the conduct of the study. Dr. Collins reports grants from the MRC, British Heart Foundation, Cancer Research UK, Wellcome Trust, The Medicines Company, Pfizer, and Merck outside the submitted work. Dr. Herrington reports grants from MRC-UK and Kidney Research UK during the conduct of the study, and grants from Boehringer Ingelheim outside the submitted work. Dr. Lewington reports grants from MRC-UK during the conduct of the study and a grant from the CDC Foundation, with support from Amgen, outside the submitted work. Dr. Emberson reports grants from the MRC during the conduct of the study and grants from Boehringer Ingelheim outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at
www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-3502.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Catharine B. Stack, PhD, MS, Deputy Editor, Statistics, reports that she has stock holdings in Pfizer, Johnson & Johnson, and Colgate-Palmolive. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose.
Reproducible Research Statement: Study protocol and data set: Not applicable.
Statistical code: Available from Dr. Emberson (e-mail,
[email protected]).
Corresponding Authors: Jonathan R. Emberson, PhD, MRC Population Health Research Unit, Nuffield Department of Population Health, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom; e-mail,
[email protected], and Jesus Alegre-Díaz, MD, Facultad de Medicina UNAM, Avenida Universidad 3000, Cd. Universitaria, 04510 Coyoacan, Mexico City, Mexico; e-mail,
[email protected].
Current Author Addresses: Ms. Gnatiuc and Drs. Clarke, Collins, and Peto: Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom. Ms. Wade and Drs. Herrington, Hill, Lewington, and Emberson: MRC Population Health Research Unit, Nuffield Department of Population Health, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.
Drs. Alegre-Díaz, Tapia-Conyer, and Kuri-Morales; Mr. Ramirez-Reyes; Mr. Garcilazo-Ávila; Mr. Gonzáles-Carballo; and Ms. Solano-Sanchez: Facultad de Medicina UNAM, Avenida Universidad 3000, Cd. Universitaria, 04510 Coyoacan, Mexico City, Mexico.
Dr. Chiquete: Salvador Zubirán National Institute of Medical Sciences and Nutrition, Vasco de Quiroga 15, Belisario Domínguez Secc 16, 14080 Mexico City, Mexico.
Author Contributions: Conception and design: L. Gnatiuc, J. Alegre-Díaz, R. Tapia-Conyer, R. Clarke, R. Peto, J.R. Emberson, P. Kuri-Morales.
Analysis and interpretation of the data: L. Gnatiuc, R. Wade, R. Clarke, R. Peto, J.R. Emberson.
Drafting of the article: L. Gnatiuc, J.R. Emberson.
Critical revision for important intellectual content: L. Gnatiuc, J. Alegre-Díaz, R. Wade, R. Ramirez-Reyes, R. Tapia-Conyer, A. Garcilazo-Ávila, E. Chiquete, C. Gonzáles-Carballo, M. Solano-Sanchez, R. Clarke, R. Collins, W.G. Herrington, M. Hill, S. Lewington, R. Peto, J.R. Emberson, P. Kuri-Morales.
Final approval of the article: L. Gnatiuc, J. Alegre-Díaz, R. Wade, R. Ramirez-Reyes, R. Tapia-Conyer, A. Garcilazo-Ávila, E. Chiquete, C. Gonzáles-Carballo, M. Solano-Sanchez, R. Clarke, R. Collins, W.G. Herrington, M. Hill, S. Lewington, R. Peto, J.R. Emberson, P. Kuri-Morales.
Statistical expertise: R. Wade, R. Peto, J.R. Emberson.
Obtaining of funding: J. Alegre-Díaz, R. Tapia-Conyer, R. Collins, R. Peto, J.R. Emberson, P. Kuri-Morales.
Administrative, technical, or logistic support: R. Ramirez-Reyes, M. Solano-Sanchez, M. Hill.
Collection and assembly of data: J. Alegre-Díaz, R. Ramirez-Reyes, R. Tapia-Conyer, W.G. Herrington, M. Hill, J.R. Emberson, P. Kuri-Morales.
This article was published at
Annals.org on 13 August 2019.
* Ms. Gnatiuc and Dr. Alegre-Díaz share first authorship.
† Drs. Emberson and Kuri-Morales share last authorship.
Regarding General and Abdominal Adiposity and Mortality in Mexico City
We read with interest and nostalgia the paper by Gnatiuc et al (1) that reported a link between abdominal adiposity and mortality in Mexicans. We reported an enhanced cardiovascular risk profile linked to visceral fat estimated by computerized tomography in this journal in 1989 (2). The enhanced morbidity and mortality linked to abdominal obesity, however, dates back several decades to Jean Vague, a French physician. There is little doubt that abdominal adiposity with its increased visceral fat and frequent steatosis identifies individuals of both genders at very high risk of metabolic and cardiovascular complications including early death. Even individuals of near normal weight with increased abdominal adiposity may be at such risk. Studies have confirmed this association across many different cultures and countries. Abdominal obesity has reached pandemic proportions. In order to address this pressing public health issue and to contain soaring costs it behooves researchers to consider the pathogenesis of abdominal adiposity.
Further, we would like to submit the following evolutionary hypothesis for the development of abdominal adiposity. A high carbohydrate diet is experienced in Asian and Hispanic cultures. As well, an increase in refined carbohydrate intake has extended to all cultures in the last few decades. This increase has been documented by the Centers for Disease control (CDC) and independent entities such as PEW research. Physicians have warned about the dangers of a high fat diet but largely ignored the potential dangers of the excessive intake of refined carbohydrates. The PURE study, a global initiative confirmed that high carbohydrate intake was linked closely to mortality, and a high fat intake had an inverse relationship to mortality (3). When low calorie diets are compared in obese diabetic patients – a low carbohydrate diet is clearly superior to a high carbohydrate diet in improving metabolic parameters and reducing visceral fat (4). Moreover, satiety may be better induced on a low carbohydrate diet than a low-fat diet. We do not discount that a plant based high carbohydrate low fat diet may also have metabolic benefits. However, since a reduction in vascular endothelial dysfunction in obesity is related to a reduction in visceral adiposity (5) additional studies addressing the benefits of a low refined carbohydrate diet are urgently needed. It is possible that physicians need a paradigm shift from the dangers of a high fat diet to the dangers of a processed-food carbohydrate diet. We look forward to the authors’ response.
References:
(1) Gnatiuc L, Alegre-Díaz J, Wade R, et al. General and Abdominal Adiposity and Mortality in Mexico City: Prospective Study of 150 000 Adults. Ann Intern Med. [Epub ahead of print 13 August 2019] doi: 10.7326/M18-3502
(2) Peiris AN, Sothmann MS, Hoffmann RG, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med. 1989 Jun 1;110(11):867-72
(3) Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017 Nov 4;390(10107):2050-2062. doi: 10.1016/S0140-6736(17)32252-3.
(4) Miyashita Y, Koide N, Ohtsuka M, et al. Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity. Diabetes Res Clin Pract. 2004 Sep;65(3):235-41.
(5) Park SH, Shim KW. Reduction in Visceral Adiposity is Highly Related to Improvement in Vascular Endothelial Dysfunction among Obese Women: An Assessment of Endothelial Function by Radial Artery Pulse Wave Analysis. Yonsei Med J. 2005 Aug 31; 46(4): 511–518. doi: 10.3349/ymj.2005.46.4.511.